decisionhealth Newsletters, Part B News - 2023 Issue 3 (March)
Prepare for change in telehealth and controlled substance Rx after the PHE
Subscribe or sign in to view the full article.
Article Overview
This article explains proposed SAMHSA and DEA rule changes that may affect telehealth-based prescribing, opioid treatment program standards, and controlled substance access after the COVID-19 public health emergency. It is intended for providers, compliance staff, and coding or billing professionals who need to track federal regulatory updates and understand which flexibilities may become permanent or expire. The discussion focuses on broad policy areas, agency timelines, comment periods, and the types of prescribing relationships and treatment settings affected.
Why This Topic Matters
The proposed rules could alter how telehealth care is delivered and how certain controlled substance prescriptions are handled after the public health emergency ends. Readers who work with behavioral health, substance use treatment, or telemedicine compliance need to know which federal agencies are changing policy and when comments or effective dates may matter.
Article Sections
-
SAMHSA plans to make two waivers permanent
This section covers proposed changes from SAMHSA related to opioid treatment program standards and post-PHE telehealth flexibilities. It discusses the agency’s broader approach to maintaining certain treatment access policies.
-
DEA intends to end some waivers
This section summarizes DEA proposals affecting telemedicine prescribing of controlled substances after the PHE. It outlines the general scope of the agency’s proposed limits and the categories of prescribing relationships involved.
-
Telemedicine organization expresses concern
This section describes industry प्रतिक्रिया to the DEA proposals and notes the public comment process. It highlights stakeholder concerns and the opportunity for feedback before final rules are issued.
-
Resources
This section lists external federal and advocacy resources related to the proposed telehealth and controlled substance policy changes. It provides reference links for readers seeking agency materials and related statements.
What You Will Learn
- Which federal agencies are proposing telehealth and controlled substance policy changes
- How the article frames post-PHE updates to opioid treatment and telemedicine prescribing
- What general categories of federal rules and comment opportunities are discussed
- Which treatment settings and prescribing situations are affected at a high level
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Telehealth providers
- Behavioral health practices
- Substance use treatment programs
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com